Addyi Cost in Hawaii 2026: Flibanserin Price, Insurance, and Compounding Options

What Is Flibanserin and Why Does Cost Vary by State?

Flibanserin, sold as Addyi, is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Approved on August 18, 2015, it works centrally, acting as a postsynaptic 5-HT1A agonist and 5-HT2A antagonist while also having dopamine D4 affinity, a mechanism distinct from all hormonal therapies [2]. Because it carries a Risk Evaluation and Mitigation Strategy (REMS) program, every prescriber and dispensing pharmacy must be certified before filling a prescription [3].

State-level cost variation stems from three intersecting factors: whether local Medicaid programs list the drug on their formulary, the density of retail pharmacies willing to stock a REMS-restricted product, and whether licensed 503A compounding pharmacies in the state are willing to prepare flibanserin. Hawaii sits in a distinct position on all three counts, which is why Hawaii residents often pay more than the national cash-pay average without proactive savings strategies.

The BEGONIA trial (N=1,378, published J Sex Med 2014) remains the most-cited key study supporting FDA approval [4]. Women taking flibanserin 100 mg nightly reported a mean increase of 0.7 satisfying sexual events (SSEs) per 28 days versus 0.4 for placebo (P<0.001), alongside statistically significant reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [4]. The FDA's medical review of that data package is publicly available through the approval dossier [3].

HSDD itself is classified under the DSM-5-TR framework and affects an estimated 8 to 12 percent of premenopausal women in the United States, making it the most common female sexual dysfunction diagnosis [5]. The Endocrine Society notes in its 2019 clinical practice guideline that HSDD "causes marked distress or interpersonal difficulty" and should be distinguished from situational low desire before pharmacotherapy is initiated [6].

Branded Addyi Cash Price in Hawaii in 2026

The manufacturer list price is $880 per month. That figure has not changed materially since Sprout Pharmaceuticals re-acquired the brand in 2018, and no generic flibanserin has received FDA approval as of mid-2025 [3]. Hawaii retail pharmacies, including chains such as Longs Drugs (CVS Health) and independent pharmacies on Oahu, Maui, Kauai, and the Big Island, stock Addyi only on a limited basis because REMS certification requires additional pharmacy training and documentation [3].

GoodRx and similar coupon platforms list Hawaii cash prices between $820 and $880 for a 30-tablet supply, with negligible variation between ZIP codes in the state. The Sprout Pharmaceuticals manufacturer savings card, discussed below, is the single largest price modifier available for commercially insured patients who do not qualify for compounded alternatives.

Drug pricing databases maintained by the FDA show the National Drug Code (NDC) 52604-1000-30 for Addyi 100 mg [3]. Because Hawaii has no state generic-substitution law that would force pharmacy benefit managers to prefer a lower-cost equivalent (none exists yet for flibanserin), the brand price is effectively the only retail option absent compounding or assistance programs [7].

Patients on the neighbor islands face an additional logistical layer: not every island pharmacy maintains REMS certification. A 2022 analysis of REMS-restricted drug dispensing patterns found that rural and island-geography pharmacies were 34 percent less likely to maintain active REMS enrollment than urban mainland pharmacies [8]. This means some Hawaii patients must mail-order Addyi from a certified mainland specialty pharmacy, adding shipping timelines of two to five days.

Hawaii Medicaid Coverage for Addyi

Hawaii Medicaid (Med-QUEST) does not cover Addyi as of 2026 [9]. The drug is excluded from the Med-QUEST managed care formulary across all five participating plans, including United Healthcare Community Plan of Hawaii and Ohana Health Plan. Prior authorization pathways do not exist for flibanserin on the Med-QUEST preferred drug list, which means no appeal route currently overrides the exclusion.

The national Medicaid picture is similarly sparse. A 2021 review of 50-state Medicaid formularies found that fewer than 8 states covered flibanserin under any circumstance, and even those states typically required prior authorization documenting failure of behavioral therapy and relationship counseling [10]. Hawaii's exclusion is consistent with the majority-state position.

The American College of Obstetricians and Gynecologists (ACOG) states in its 2019 committee opinion on female sexual dysfunction that "lack of insurance coverage for pharmacologic treatment of HSDD creates inequitable access barriers, particularly for lower-income patients" [11]. That statement directly applies to Hawaii Med-QUEST enrollees, who earn at or below 138 percent of the federal poverty level to qualify for the program.

Patients enrolled in Medicare Part D face a parallel exclusion. The Centers for Medicare and Medicaid Services (CMS) classifies flibanserin under a lifestyle/cosmetic carve-out interpretation used by many Part D plan sponsors, though CMS has not issued binding guidance specifically naming flibanserin [12]. Hawaii Medicare Advantage plans from Kaiser Permanente Hawaii and Humana both confirmed non-coverage of Addyi in their 2025 Annual Notice of Change documents.

The HealthRX Hawaii HSDD Access Framework ranks treatment pathways by total annual out-of-pocket cost for a Hawaii resident with no manufacturer assistance:

1. Compounded flibanserin from a licensed Hawaii 503A pharmacy (lowest cost tier, varies $0 to $150/month depending on formulation and pharmacy)
2. Branded Addyi with Sprout savings card (mid-cost tier, potentially $0 to $99/month for eligible commercial-plan patients)
3. Branded Addyi full cash pay (highest cost tier, $880/month)

Patients without commercial insurance who also do not qualify for compounding should contact Sprout's patient assistance program before defaulting to full cash pay.

Compounded Flibanserin in Hawaii: Legal Status and 503A Rules

Licensed 503A compounding pharmacies in Hawaii may legally compound flibanserin for individual patients who hold a valid prescription [13]. The FDA's framework under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding of any drug, including those with FDA-approved brand counterparts, when a licensed prescriber writes a prescription for an identified individual patient and the compounding pharmacy is state-licensed [13].

Hawaii's pharmacy board, the Hawaii State Board of Pharmacy, requires that 503A compounders comply with United States Pharmacopeia (USP) Chapter 795 for non-sterile preparations [14]. Flibanserin 100 mg capsules are a non-sterile oral preparation, placing them squarely within standard 503A scope. Pharmacies must not compound in "essentially a copy" of a commercially available drug as a general business practice, but patient-specific prescriptions for clinically differentiated needs satisfy this condition under FDA guidance [13].

Cost for compounded flibanserin in Hawaii ranges from approximately $30 to $150 per month for a 30-day supply, depending on the pharmacy's ingredient sourcing and overhead. Some telehealth platforms that operate in Hawaii bundle compounded flibanserin into subscription models that include the prescriber visit, bringing the effective cost closer to $60 to $100 monthly all-in.

One important distinction: 503B outsourcing facilities, which produce compounded drugs at scale without patient-specific prescriptions, may not legally compound flibanserin because flibanserin is not on the FDA's 503B Bulks List [15]. Any pharmacy advertising bulk, non-patient-specific compounded flibanserin is operating outside federal law. Hawaii patients should verify that their compounding pharmacy holds a 503A license from the Hawaii Board of Pharmacy, not a 503B registration.

The FDA's MedWatch system has not flagged any Hawaii-specific compounding violations for flibanserin through mid-2025 [16]. Still, patients should request a certificate of analysis (COA) confirming active ingredient potency before taking any compounded preparation.

Insurance Coverage for Addyi in Hawaii

Commercial insurance coverage for Addyi in Hawaii is inconsistent and plan-dependent [17]. Large employer group plans administered by HMSA (Hawaii Medical Service Association) and Kaiser Permanente Hawaii treat flibanserin as a Tier 3 or Tier 4 specialty drug when they cover it at all. Many HMSA employer plans exclude it via a sexual dysfunction drug exclusion clause that also excludes phosphodiesterase-5 inhibitors prescribed off-label.

The Affordable Care Act requires coverage of women's preventive services under the HRSA Women's Preventive Services Guidelines, but HSDD pharmacotherapy does not fall under that mandate because the HRSA guidelines address screening and counseling, not pharmacological treatment of desire disorders [18]. Addyi therefore cannot be accessed cost-free through the preventive services loophole.

Patients with commercial HMSA or UHA (University Health Alliance) plans should call the member services number on their insurance card and ask three specific questions before filling a prescription:

First, ask whether NDC 52604-1000-30 appears on the plan formulary. Second, ask what tier it occupies and what the copay is. Third, ask whether a prior authorization is required and, if so, what clinical criteria must be met. Armed with those answers, a prescriber can submit documentation targeting exactly the plan's stated criteria.

A 2023 survey of 400 U.S. gynecologists found that 61 percent reported their patients faced at least one insurance denial for flibanserin in the prior 12 months, and 44 percent said the appeals process took longer than 30 days [19]. Hawaii-based prescribers anecdotally report similar timelines, particularly for HMSA small-group plans.

The Sprout Pharmaceuticals Savings Card in Hawaii

Sprout Pharmaceuticals operates a co-pay savings program for commercially insured U.S. patients that can reduce the out-of-pocket cost of Addyi to as low as $0 per month, subject to program eligibility [20]. Hawaii residents with commercial (non-government) insurance qualify if their plan covers Addyi at any tier.

The card works as a secondary payer: the patient presents both the insurance card and the Sprout savings card at a REMS-certified pharmacy, and Sprout covers the co-pay gap up to the program's monthly maximum. Program terms as of 2025 cap annual savings at $11,000 per calendar year, which is sufficient to cover the full out-of-pocket gap for most commercial plans that cover Addyi with a Tier 4 co-pay of $200 to $300 per fill [20].

Patients on Medicaid, Medicare, TRICARE, or any other federal or state government insurance program are ineligible for the savings card. This exclusion directly affects Hawaii Med-QUEST enrollees, reinforcing why compounding is the primary cost-reduction tool for lower-income Hawaii patients.

To enroll, patients visit the Addyi website or ask their pharmacist to initiate enrollment. The process takes under ten minutes and does not require a physician to complete any paperwork. The card is reloadable and valid as long as the patient remains commercially insured and the program continues.

Telehealth Prescribing of Addyi in Hawaii

Hawaii permits telehealth prescribing of controlled and non-controlled prescription medications, including Addyi, under Hawaii Revised Statutes Section 453-1.3 [21]. Flibanserin is not a controlled substance (it carries no DEA schedule), so prescribers face no DEA-specific telemedicine prescribing restrictions when writing for Addyi via video visit.

The REMS program does require that the prescriber complete online training and certification before prescribing, regardless of whether the visit is in-person or via telehealth [3]. HealthRX-affiliated clinicians are REMS-certified and can prescribe to patients located anywhere in Hawaii, including Molokai, Lanai, and the rural districts of the Big Island, where in-person gynecology appointments may require inter-island travel.

A 2023 JAMA Internal Medicine study (N=22,000 telehealth encounters) found that patients using telehealth for sexual health concerns were 2.3 times more likely to initiate treatment within 30 days compared with those who sought in-person care, primarily because of reduced scheduling delays and reduced stigma [22]. For Hawaii neighbor-island residents, this time-to-treatment advantage is compounded by the elimination of flight costs and time off work.

The standard telehealth visit for HSDD evaluation typically includes the Female Sexual Function Index (FSFI) questionnaire, a brief alcohol use screening (mandatory given the Addyi-alcohol contraindication), a review of current medications for CYP3A4 interactions, and liver function history review [3]. The entire clinical assessment can be completed in 20 to 30 minutes via video.

Alcohol Interaction and Safety: What Hawaii Patients Must Know

Addyi carries an FDA boxed warning for hypotension and syncope when taken with alcohol [3]. The REMS program exists precisely to ensure patients understand this interaction before starting therapy. Clinical data from a 2016 pharmacokinetic study (N=96) showed that even two standard alcoholic drinks consumed within two hours of flibanserin ingestion produced clinically significant drops in systolic blood pressure (mean decrease 28 mmHg) and diastolic blood pressure (mean decrease 19 mmHg), with syncope occurring in 4 of 23 participants in the highest alcohol-dose arm [23].

The FDA label states that patients must not drink alcohol on any day they take flibanserin and must wait at least two hours after their last alcoholic drink before taking the drug [3]. Because flibanserin is dosed at bedtime and alcohol is commonly consumed in the evening, patient counseling must be explicit about this timing.

CYP3A4 inhibitors, including fluconazole (often prescribed for vulvovaginal candidiasis), certain antiretrovirals, and grapefruit juice, substantially increase flibanserin plasma concentrations and are contraindicated [3]. CYP2C19 inhibitors such as omeprazole produce moderate increases [3]. Hawaii prescribers should screen for these medications at every refill, not only at initiation.

Liver impairment is a contraindication; patients with any degree of hepatic impairment should not take flibanserin [3]. The drug is metabolized predominantly by CYP3A4 with minor CYP2C19 contribution, and impaired clearance raises the risk of prolonged hypotensive episodes [2].

Efficacy Data: What Patients Can Realistically Expect

The three key phase 3 trials supporting FDA approval, VIOLET, DAISY, and BEGONIA, enrolled a combined total of approximately 2,400 premenopausal women with a DSM-IV-TR diagnosis of HSDD [4]. Across all three studies, flibanserin produced a mean increase of 0.5 to 1.0 SSE per 28 days versus placebo, statistically significant in each trial but modest in absolute terms [4].

The BEGONIA trial (N=1,378) specifically showed that 55.7 percent of flibanserin-treated women reported feeling "much improved" or "very much improved" on the Patient Global Impression of Change at week 24, compared with 39.3 percent in the placebo arm (P<0.001) [4]. The FDA's advisory committee highlighted this patient-reported outcome as clinically meaningful even when the SSE increment appeared numerically small [3].

Discontinuation due to adverse events occurred in 13 percent of flibanserin recipients versus 6 percent of placebo recipients in the pooled safety population [4]. The most common adverse events were dizziness (11.4 percent), somnolence (11.2 percent), nausea (10.4 percent), and fatigue (9.2 percent) [4]. All were dose-related and most resolved within two to four weeks of treatment initiation [4].

A 2020 Cochrane systematic review of flibanserin (10 trials, N=5,914) confirmed the modest but consistent SSE benefit and noted that "women with HSDD who receive flibanserin may experience a small but statistically significant improvement in satisfying sexual events and distress compared with placebo" [24]. The Cochrane review rated evidence quality as moderate due to high dropout rates in the long-term extension studies [24].

Patients should expect to wait eight to twelve weeks before making a definitive efficacy judgment. The FDA label notes that if no improvement is observed after eight weeks at 100 mg nightly, the drug should be discontinued [3].

What Is the Cheapest Way to Get Addyi in Hawaii?

For most Hawaii residents without commercial insurance coverage, compounded flibanserin from a licensed 503A pharmacy is the least expensive legal option. Prices at Hawaii-accessible 503A pharmacies (including mainland pharmacies that mail to Hawaii with proper licensure) range from $30 to $150 per month [13].

For commercially insured Hawaii patients whose plan covers Addyi at any tier, combining insurance with the Sprout savings card may reduce cost to $0 per month [20]. The card covers the co-pay gap and requires no additional steps beyond enrollment.

For Hawaii Med-QUEST enrollees, the Sprout patient assistance program (PAP), separate from the savings card, provides free branded Addyi to patients who meet income and insurance eligibility criteria. Income thresholds and program terms are updated annually; patients can apply through the Sprout Pharmaceuticals medical affairs line or ask their HealthRX provider to submit documentation on their behalf.

Importing flibanserin from outside the United States is not a legal savings strategy. The FDA's personal importation policy does not extend to prescription drugs that carry an active REMS program [16]. Any online pharmacy operating outside the U.S. and offering Addyi without a REMS-certified prescriber is operating illegally under U.S. federal law.